This article has Open Peer Review reports available.
ACTN4 and the pathways associated with cell motility and adhesion contribute to the process of lung cancer metastasis to the brain
- Yufei Gao†1,
- Guanghu Li†2,
- Liankun Sun3,
- Yichun He1,
- Xiaoyan Li4,
- Zhi Sun5,
- Jihan Wang3,
- Yang Jiang6Email author and
- Jingwei Shi5Email author
© Gao et al.; licensee BioMed Central. 2015
Received: 25 November 2014
Accepted: 31 March 2015
Published: 12 April 2015
The aim of this study was to identify critical gene pathways that are associated with lung cancer metastasis to the brain.
The RNA-Seq approach was used to establish the expression profiles of a primary lung cancer, adjacent benign tissue, and metastatic brain tumor from a single patient. The expression profiles of these three types of tissues were compared to define differentially expressed genes, followed by serial-cluster analysis, gene ontology analysis, pathway analysis, and knowledge-driven network analysis. Reverse transcription–polymerase chain reaction (RT-PCR) was used to validate the expression of essential candidate genes in tissues from ten additional patients.
Differential gene expression among these three types of tissues was classified into multiple clusters according to the patterns of their alterations. Further bioinformatic analysis of these expression profile data showed that the network of the signal transduction pathways related to actin cytoskeleton reorganization, cell migration, and adhesion was associated with lung cancer metastasis to the brain. The expression of ACTN4 (actinin, alpha 4), a cytoskeleton protein gene essential for cytoskeleton organization and cell motility, was significantly elevated in the metastatic brain tumor but not in the primary lung cancer tissue.
The signaling pathways involved in the regulation of cytoskeleton reorganization, cell motility, and focal adhesion play a role in the process of lung cancer metastasis to the brain. The contribution of ACTN4 to the process of lung cancer metastasis to the brain could be mainly through regulation of actin cytoskeleton reorganization, cell motility, and focal adhesion.
Metastatic brain tumors are the most common type of brain tumor in adults and are associated with a poor survival of patients (median survival time = 3–6 months) . A total of 40–50% of brain metastases originate from lung cancer . Studies of differential gene expression between brain metastases and primary lung cancer have suggested that many genes may be involved in the brain metastasis of lung cancer. Using a cDNA microarray approach, more than 200 genes, including genes encoding plasma membrane proteins, antigen proteins, and cytoskeletal proteins, have been found to be differentially expressed between a metastatic brain tumor and a lung adenocarcinoma . These genes function in cell interaction, attachment, and motility.
Actinin, alpha 4 (ACTN4), a nonmuscle cytoskeleton protein, has been frequently reported to be associated with cell motility and cancer metastasis. Honda et al. have suggested that cytoplasmic ACTN4 increases cell motility and is associated with a high metastatic potential and a poor prognosis of cancer based on their studies on multiple cancer cell lines, including lung cancer cell lines, and 61 patients with early-stage breast cancer . Since then, ACTN4 has been reported to be associated with the progression and metastasis of many types of cancer, including breast , colorectal , pancreatic , lung [8-10], brain , bladder [12,13], and ovarian cancers [14-16] and salivary gland carcinoma . In addition, ACTN4 was found to be highly expressed in a poor survival group of patients with non-small cell lung cancer, suggesting that ACTN4 is a significant prognostic predictor in this cohort of patients . A novel alternative splice variant RNA of ACTN4 has been suggested to be a candidate diagnostic marker of human small cell lung cancer  and a prognostic factor for patients with high-grade neuroendocrine pulmonary tumors . However, in contrast to the aforementioned function of ACTN4 as a positive regulator of tumorigenesis or cancer metastasis, several studies have suggested that ACTN4 may function like a tumor suppressor to suppress malignant behaviors of cancer cells [18,19]. Therefore, the association of ACTN4 expression with tumorigenicity and cancer metastasis needs to be further investigated in the clinic.
In order to define the critical signaling pathways and genes that contribute to the brain metastasis of lung cancer, we used the RNA-Seq approach to investigate the expression profiles of three types of tissues (primary lung cancer, adjacent benign lung tissue, and metastatic brain tissue) from one patient. Subsequently, a series of bioinformatic analyses were performed with the RNA-Seq data to identify differentially expressed genes among these three types of tissues and to discover the critical pathways and genes responsible for the brain metastasis of lung cancer.
A 47-year-old female patient was found to have a space-occupying lesion in her lung in January 2009. A diagnosis of poorly/moderately differentiated adenocarcinoma with a primary tumor–lymph node–distant metastasis stage of T2N1Mx in the right middle lobe of the lung was made in January 2010. Resection of the lower part of the right middle lobe was conducted and followed by chemotherapy. The metastatic tumor at the right frontal lobe of the brain was found and resected in December 2010. Pathological analyses showed that the tumor was a poorly/moderately differentiated adenocarcinoma that had metastasized from the lung. The adjacent benign lung tissue (N16), the original lung cancer (T16), and the metastatic brain tumor (T30) were collected. This study was approved by the institutional review board of China-Japan Union Hospital of Jilin University and conducted in accordance with the ethical guidelines of the Declaration of Helsinki. The patient had signed a consent form before the study. In addition, we collected lung cancer and para-tumor tissues from ten patients for the confirmation study.
RNA isolation and RNA-seq library preparation
Total RNA was isolated from the tissues using a Trizol reagent (Invitrogen, Carlsbad, CA, USA). The RNA quality was assessed using a Bioanalyzer 2200 (Agilent, Santa Clara, CA, USA), and the samples were stored at −80°C until use. The RNA integrity numbers (RIN) of these RNA samples were more than 8.0 and were appropriate for cDNA library construction.
cDNA library construction and sequencing
The TruSeqTM RNA Sample Preparation Kit (Illumina, Inc.) was used to construct the cDNA libraries for these RNA samples, according to the manufacturer’s instructions. Briefly, oligo(dT) magnetic beads were applied to purify mRNA using 10 μg of total RNA, and the purified mRNA was subsequently fragmented into sizes of 200–500 bp using divalent cations at 94°C for 5 min. Reverse transcription (RT) of the first-strand cDNA from the RNA fragments was performed using SuperScript II reverse transcriptase and random primers. The second strand cDNA synthesis was performed using DNA polymerase I and RNase H. The synthesized cDNA fragments were then end-repaired by adding a single “A” base ligated with indexed adapters. These end-repaired cDNA fragments were purified and enriched by the polymerase chain reaction (PCR). The final cDNA libraries were generated by size selection through 2% agarose gel electrophoresis and quantified by a Bioanalyzer 2200. The tagged cDNA libraries were pooled in an equal ratio and loaded in a single lane of the Illumina HiSeqTM 2000 for paired-end sequencing.
The endogenous control β-actin was used as a control for RT-PCR amplification measurement of ACTN4 expression. RT-PCR primers were β-actin (5′-CTGGAACGGTGAAGGTGACA-3′ and 5′-AAGGGACTTCCTGTAACAATGCA-3′) and ACTN4 (5′-ACAAGCCCAACCTGGAC-3′ and 5′-GGTGCGGGCAATGGTG-3′). The cDNA was generated using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) and oligo(dT) primers, according to the manufacturer’s instructions. qPCR amplification was performed with the following conditions: 2 min at 50°C, 10 min at 95°C, and 50 cycles of 15 s at 95°C, and 1 min at 60°C. The conditions for the melting curve analysis were 1 min at 90°C, 30 s at 55°C, and 30 s at 95°C.
The DEGseq algorithm was applied to filter the differentially expressed genes with a fold change > 2, P < 0.5, and false discovery rate (FDR) < 0.05 . Gene ontology (GO) analysis was performed according to the GO annotations from NCBI (http://www.ncbi.nlm.nih.gov/), UniProt (http://www.uniprot.org/), and Gene Ontology (http://www.geneontology.org/). The pathway analyses were performed to determine the significant pathways associated with the differentially expressed genes according to the KEGG database. Fisher’s exact test, P values, and FDRs were applied in the GO and pathway analyses, according to a previous study . Series cluster analysis was performed to classify the differentially expressed genes in eight clusters based on the reads per kb per million reads (RPKM) change tendency of genes in these three types of tissues (N16, T16, and T30), according to a previous study . For example, the genes with the following expression pattern were classified into Cluster 1: expression in N16 > expression in T16 = expression in T30. The Path-Act-Network analyses were performed to reveal the interactive network among the pathways with enriched differentially expressed genes based on the KEGG database, including the metabolism, membrane transport, signal transduction, and cell cycle pathways . Cytoscape software was used to generate the graphical representations of the pathways . Gene-Act-Net analyses were conducted to reveal the network of the differentially expressed genes based on the interactions among the genes, proteins, and compounds included in the KEGG database.
Read numbers and mapping rates for the data from these three types of tissues
Unique mapped reads
Repeat mapped reads
Unique mapping rates
Differentially expressed genes among these three types of tissues
The RNA-Seq data from these three types of tissues that had passed the aforementioned quality control were mapped to the reference genome, followed by the statistical analyses and expression analyses based on the RPKM values and upper-quartile normalization (Additional file 1: Table S1), according to a previous study . Subsequently, differentially expressed genes were further analyzed using the DEGSeq method. We found that there were more than 900 differentially expressed genes between N16 and T16 (Additional file 2: Table S2) and more than 800 differentially expressed genes between N16 and T30 (Additional file 3: Table S3). Notably, the expression of ACTN4 did not show a significant difference between N16 and T16, but it was significantly increased in T30 (P = 2.26 × 10−17, FDR = 6.53 × 10−15).
Gene Ontology (GO) analysis
qRT-PCR validation for ACTN4 expression in these three types of tissues
The expression profiles of primary lung cancer, adjacent benign lung tissues, and brain metastatic tumor tissues from a single patient were explored using the RNA-Seq technique. A series of bioinformatic analyses revealed gene functions and signaling pathways essential for lung cancer development and brain metastasis. Among these significant genes and pathways, ACTN4, encoding a nonmuscle actin cytoskeleton protein, and the pathway involved in regulation of actin cytoskeleton appeared to play a pivotal role in the process of lung cancer metastasis to the brain.
Overall, the quality of the RNA-Seq data and read mapping in our current study met the requirements for the bioinformatic analyses. However, the total reads and the mapping rate for the adjacent benign tissue were not as good as those of the primary lung cancer and the metastatic brain tumor tissues, probably resulting from the limited amount of the benign tissue and the total RNA available for the RNA-Seq approach. Nevertheless, appropriate bioinformatic analyses were performed on the RNA-Seq data from this study.
Differential gene expression analysis based on the RPKM values with upper-quartile normalization revealed that many genes were differentially expressed among these three types of tissues. The RPKM values refer to the reads per kb per million reads, according to a previous study . These differentially expressed genes were classified into eight clusters according to their changed expression patterns in these three types of tissues. The genes in cluster 4 are likely candidate genes that are indispensable for lung cancer metastasis to the brain because these genes presented a significantly increased expression in the metastatic brain tumors but not in the primary lung cancer tissue or the benign tissue. The genes in cluster 4 involve a variety of cellular functions, including cytoskeleton-dependent intracellular transport, membrane-to-membrane docking, actin filament bundle assembly, cell-cell adhesion, and actin cytoskeleton organization. The pathway analysis showed similar results for the cluster 4 genes. These genes are mostly involved in the signaling pathways associated with extracellular molecular interaction, cellular adhesion, adherens junction, and cytoskeleton organization. Interestingly, ACTN4, encoding the alpha-actinin-4 protein, is among cluster 4 genes. Alteration of ACTN4 expression was further validated in these three types of tissues. ACTN4 has been shown to play important roles in cytoskeleton organization, cell adhesion, and cell migration. It has been suggested that ACTN4 is indispensable for mononuclear phagocyte response both in inflammation and tumor invasion processes . A recent study also supported that ACTN4, particularly relying on its C-terminal tail, mediates the cytoskeleton to the adhesion site during cell migration . Our results demonstrated that these functions of ACTN4 contribute to the process of lung cancer metastasis to the brain.
Of note, another alpha-actinin gene, ACTN1, also appeared in cluster 4 and presented a similar altered expression pattern as ACTN4 in these three types of tissues. Indeed, ACTN1 has been reported to be essential for cytoskeleton organization and cell motility in some types of cells . Foley and Young recently have shown that ACTN4 and ACTN1 form a heterodimer in many types of cells . However, it also has been shown that ACTN1 and ACTN4 contribute to distinct malignant properties of astrocytoma cells and that ACTN4 may be more important for cell motility and cell adhesion in some cell lines .
In contrast to the functions of the genes in cluster 4, the genes in cluster 1 presented distinct functions such as regulation of reactive oxygen species, response to interlukin-6, and regulation of the activation of JAK2 kinase activity. Accordingly, the pathway analysis results were also distinct for the genes in cluster 1 and cluster 4. These results support our hypothesis that the genes in cluster 1 likely include candidate genes critical for tumorigenicity and that the genes in cluster 4 likely include candidate genes indispensable for metastasis.
The Pathway-Act-Network analysis based on the RNA-Seq data from the three types of tissues suggested that the pathways associated with the regulation of actin cytoskeleton are the pivotal players during lung cancer metastasis to the brain. Our data indicated that alteration of these actin cytoskeleton pathways could contribute to lung cancer metastasis to the brain through interacting with several other pathways involved in cellular processes, such as focal adhesion, adherens junction, and ECM-receptor interaction. The important function of the cytoskeleton in cancer metastasis has been widely recognized . The results from a study of transendothelial migration of small cell lung cancer cells across human brain microvascular endothelial cells showed that the Rho/ROCK pathway contributes to actin cytoskeleton reorganization . Consistent with this report, ras homolog family member C (RHOC) also appeared among the genes in cluster 4, and its expression was increased in the brain metastatic tumor but not in the primary lung cancer tissue. ACTN4 is a critical gene related to actin cytoskeleton regulation and has been reported by multiple studies to play an important role in cell adhesion, cell motility, and cancer metastasis [4,5,12,15,17,18]. It also has been suggested that ACTN4 may interact with Rho family members to regulate cell motility and cancer metastasis through regulating cytoskeleton organization and focal adhesion [11,27,28,30,31]. In short, the bioinformatic analysis data revealed that the pathways involved with actin cytoskeleton regulation were pivotal pathways in the Pathway-Act-Network and that the ACTN4 gene was one of the key players in the Gene-Act-Network. Our current data are consistent with many previous studies, including a microarray and immunostaining data on ACTN4 and its association with pathways contributing to lung cancer metastasis [8,10]. Our study provided the first RNA-Seq data to support the essential function of the ACTN4 gene and the relevant cytoskeleton organization pathways in the brain metastasis of lung carcinoma. However, the fact that only one patient’s samples were used is a major limitation of our current study. A future study with more samples will help to confirm and support our current findings.
In summary, the expression profiles of the primary lung cancer, adjacent benign lung tissue, and metastatic brain tissue from one patient were established using an RNA-Seq assay, and subsequent bioinformatic analyses demonstrated that the actinin gene ACTN4 and the pathways involved in the regulation of cytoskeleton organization, cell motility, and focal adhesion are indispensable for the process of lung cancer metastasis to the brain. ACTN4 contributes to the brain metastasis of lung cancer mainly through regulating actin cytoskeleton organization, cell motility, and focal adhesion.
Written informed consent was obtained from the patient for publication of this article and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
This work was supported in part by grants from the National Natural Science Foundation of China (#81372696), China Postdoctoral Science Foundation (#2013 M541314), Jilin Provincial Science and Technology Department (#20090175 and #20100733), Scientific Research Foundation for Returned Overseas Chinese Scholars, State Education Ministry (#2009-36), Health and Family Planning Commission of Jilin Province (#2010Z068), Scientific Research Foundation for the Returned Overseas Chinese Scholars, Human Resources and Social Security Department of Jilin Province (#2012-2014), Postdoctoral Science Foundation of Jilin Province, and Human Resources and Social Security Department of Jilin Province (2012).
- Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500.View ArticlePubMedGoogle Scholar
- Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94:2698–705.View ArticlePubMedGoogle Scholar
- Kikuchi T, Daigo Y, Ishikawa N, Katagiri T, Tsunoda T, Yoshida S, et al. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol. 2006;28:799–805.PubMedGoogle Scholar
- Honda K, Yamada T, Endo R, Ino Y, Gotoh M, Tsuda H, et al. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol. 1998;140:1383–93.View ArticlePubMedPubMed CentralGoogle Scholar
- Khurana S, Chakraborty S, Cheng X, Su Y-T, Kao H-Y. The actin-binding protein, actinin alpha 4 (ACTN4), is a nuclear receptor coactivator that promotes proliferation of MCF-7 breast cancer cells. J Biol Chem. 2011;286:1850–9.View ArticlePubMedGoogle Scholar
- Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, Hasegawa F, et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology. 2005;128:51–62.View ArticlePubMedGoogle Scholar
- Kikuchi S, Honda K, Tsuda H, Hiraoka N, Imoto I, Kosuge T, et al. Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas. Clin Cancer Res. 2008;14:5348–56.View ArticlePubMedGoogle Scholar
- Yamagata N, Shyr Y, Yanagisawa K, Edgerton M, Dang TP, Gonzalez A, et al. A training–testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res. 2003;9:4695–704.PubMedGoogle Scholar
- Honda K, Yamada T, Seike M, Hayashida Y, Idogawa M, Ino Y, et al. Alternative splice variant of actinin-4 in small cell lung cancer. Oncogene. 2004;23:5257–62.View ArticlePubMedGoogle Scholar
- Miyanaga A, Honda K, Tsuta K, Masuda M, Yamaguchi U, Fujii G, et al. Diagnostic and prognostic significance of the alternatively spliced ACTN4 variant in high-grade neuroendocrine pulmonary tumours. Ann Oncol. 2013;24:84–90.View ArticlePubMedGoogle Scholar
- Quick Q, Skalli O. Alpha-actinin 1 and alpha-actinin 4: contrasting roles in the survival, motility, and RhoA signaling of astrocytoma cells. Exp Cell Res. 2010;316:1137–47.View ArticlePubMedGoogle Scholar
- Koizumi T, Nakatsuji H, Fukawa T, Avirmed S, Fukumori T, Takahashi M, et al. The role of actinin-4 in bladder cancer invasion. Urology. 2010;75:357–64.View ArticlePubMedGoogle Scholar
- Yoshii H, Ito K, Asano T, Horiguchi A, Hayakawa M, Asano T. Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer. Oncol Rep. 2013;30:1073–80.PubMedGoogle Scholar
- Yamamoto S, Tsuda H, Honda K, Kita T, Takano M, Tamai S, et al. Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type. Mod Pathol. 2007;20:1278–85.View ArticlePubMedGoogle Scholar
- Yamamoto S, Tsuda H, Honda K, Onozato K, Takano M, Tamai S, et al. Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance. Mod Pathol. 2009;22:499–507.View ArticlePubMedGoogle Scholar
- Barbolina MV, Adley BP, Kelly DL, Fought AJ, Scholtens DM, Scholtens DM, et al. Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma. Lab Invest. 2008;88:602–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Watabe Y, Mori T, Yoshimoto S, Nomura T, Shibahara T, Yamada T, et al. Copy number increase of ACTN4 is a prognostic indicator in salivary gland carcinoma. Cancer Med. 2014;3:613–22.View ArticlePubMedPubMed CentralGoogle Scholar
- Hara T, Honda K, Shitashige M, Ono M, Matsuyama H, Naito K, et al. Mass spectrometry analysis of the native protein complex containing actinin-4 in prostate cancer cells. Mol Cell Proteomics. 2007;6:479–91.View ArticlePubMedGoogle Scholar
- Nikolopoulos SN, Spengler BA, Kisselbach K, Evans AE, Biedler JL, Ross RA. The human non-muscle alpha-actinin protein encoded by the ACTN4 gene suppresses tumorigenicity of human neuroblastoma cells. Oncogene. 2000;19:380–6.View ArticlePubMedGoogle Scholar
- Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.View ArticlePubMedPubMed CentralGoogle Scholar
- Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, et al. A systems biology approach for pathway level analysis. Genome Res. 2007;17:1537–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Ramoni MF, Sebastiani P, Kohane IS. Cluster analysis of gene expression dynamics. Proc Natl Acad Sci U S A. 2002;99:9121–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Amin N, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.View ArticlePubMedPubMed CentralGoogle Scholar
- Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by rna-seq. Nat Methods. 2008;5(7):621–8.View ArticlePubMedGoogle Scholar
- Magdolen U, Schroeck F, Creutzburg S, Schmitt M, Magdolen V. Non-muscle alpha-actinin-4 interacts with plasminogen activator inhibitor type-1 (PAI-1). Biol Chem. 2004;385:801–8.View ArticlePubMedGoogle Scholar
- Shao H, Travers T, Camacho CJ, Wells A. The carboxyl tail of alpha-actinin-4 regulates its susceptibility to m-calpain and thus functions in cell migration and spreading. Int J Biochem Cell Biol. 2013;45:1051–63.View ArticlePubMedPubMed CentralGoogle Scholar
- Sen S, Dong M, Kumar S. Isoform-specific contributions of alpha-actinin to glioma cell mechanobiology. PLoS One. 2009;4, e8427.View ArticlePubMedPubMed CentralGoogle Scholar
- Foley KS, Young PW. An analysis of splicing, actin-binding properties, heterodimerization and molecular interactions of the non-muscle α-actinins. Biochem J. 2013;452:477–88.View ArticlePubMedGoogle Scholar
- Fife CM, McCarroll JA, Kavallaris M. Movers and shakers: cell cytoskeleton in cancer metastasis. Br J Pharmacol. 2014. [Epub ahead of print].Google Scholar
- Li B, Zhao W-D, Tan Z-M, Fang W-G, Zhu L, Chen YH. Involvement of Rho/ROCK signalling in small cell lung cancer migration through human brain microvascular endothelial cells. FEBS Lett. 2006;580:4252–60.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.